Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20767834 | 0.99 | RAB9A (0.53) | RAB9AKMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL20767851 | 0.88 | SMN1; SMN2 (0.46) | RAB9AKMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL16679030 | 0.88 | SMN1; SMN2 (0.46) | RAB9AKMT2ASMN1; SMN2MAPTLMNA | |
| Hydrochloric Acid SCHEMBL20767825 | 0.88 | SMN1; SMN2 (0.45) | RAB9AKMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL16679139 | 0.86 | RAB9A (0.50) | RAB9AKMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL20972833 | 0.85 | RAB9A (0.46) | RAB9AKMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL14705750 | 0.80 | RAB9A (0.38) | RAB9AKMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL14705888 | 0.79 | KMT2A (0.48) | RAB9AKMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL16679740 | 0.79 | POLB (0.62) | KMT2AHPGDALDH1A1MEN1NPC1 | |
| SCHEMBL16679379 | 0.79 | RAB9A (0.52) | RAB9AKMT2ASMN1; SMN2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221190-B2 | Biguanide compounds and use thereof | IMMUNOMET THERAPEUTICS INC. (US) | 2019-03-05 | — | — | US | claimed |
| US-20150126518-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-05-07 | — | — | US | claimed |
| US-20190144464-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2019-05-16 | — | — | US | disclosed |
| US-10221190-B2 | Biguanide compounds and use thereof | IMMUNOMET THERAPEUTICS INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221190-B2 | Biguanide compounds and use thereof | IMMUNOMET THERAPEUTICS INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20150126518-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-05-07 | — | — | US | disclosed |
| US-20150126518-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-05-07 | — | — | US | disclosed |
| US-20150126518-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144464-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | GCKR, GCG, SLC5A2 | RAB9A 1910/4885KMT2A 3654/4885SMN1; SMN2 3490/4885 |
| US-20150126518-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | GCKR, GCG, SLC5A2 | RAB9A 1910/4885KMT2A 3654/4885SMN1; SMN2 3490/4885 |
| US-10221190-B2 | Biguanide compounds and use thereof | GCKR, GCG, SLC5A2 | RAB9A 1910/4885KMT2A 3654/4885SMN1; SMN2 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.